British Journal of Pharmacology,
Journal Year:
2019,
Volume and Issue:
176(18), P. 3489 - 3507
Published: Jan. 24, 2019
Dysfunction
of
cell
bioenergetics
is
a
common
feature
neurodegenerative
diseases,
the
most
which
Alzheimer's
disease
(AD).
Disrupted
energy
utilization
implicates
mitochondria
at
its
nexus.
This
review
summarizes
some
evidence
that
points
to
faulty
mitochondrial
function
in
AD
and
highlights
past
current
therapeutic
development
efforts.
Classical
neuropathological
hallmarks
(β-amyloid
τ)
sporadic
risk
genes
(APOE)
may
trigger
disturbance,
yet
dysfunction
incite
pathology.
Preclinical
clinical
efforts
have
overwhelmingly
centred
on
amyloid
pathway,
but
trials
reveal
clear-cut
benefits.
therapies
aimed
are
few
concentrate
reversing
oxidative
stress
death
pathways.
Novel
research
boosting
bioenergetic
offer
an
alternative
treatment
strategy.
Enhancing
preclinical
models
yield
widespread
favourable
effects
could
benefit
persons
with
AD.
LINKED
ARTICLES:
article
part
themed
section
Therapeutics
for
Dementia
Disease:
New
Directions
Precision
Medicine.
To
view
other
articles
this
visit
http://onlinelibrary.wiley.com/doi/10.1111/bph.v176.18/issuetoc.
Journal of Alzheimer s Disease,
Journal Year:
2017,
Volume and Issue:
57(4), P. 1105 - 1121
Published: Jan. 6, 2017
Alzheimer's
disease
(AD)
is
a
devastating
neurodegenerative
disorder
without
cure.
Most
AD
cases
are
sporadic
where
age
represents
the
greatest
risk
factor.
Lack
of
understanding
mechanism
hinders
development
efficacious
therapeutic
approaches.
The
loss
synapses
in
affected
brain
regions
correlates
best
with
cognitive
impairment
patients
and
has
been
considered
as
early
that
precedes
neuronal
loss.
Oxidative
stress
recognized
contributing
factor
aging
progression
multiple
diseases
including
AD.
Increased
production
reactive
oxygen
species
(ROS)
associated
age-
disease-dependent
mitochondrial
function,
altered
metal
homeostasis,
reduced
antioxidant
defense
directly
affect
synaptic
activity
neurotransmission
neurons
leading
to
dysfunction.
In
addition,
molecular
targets
by
ROS
include
nuclear
DNA,
lipids,
proteins,
calcium
dynamics
cellular
architecture,
receptor
trafficking
endocytosis,
energy
homeostasis.
Abnormal
metabolism
turn
could
accumulation
amyloid-β
(Aβ)
hyperphosphorylated
Tau
protein,
which
independently
exacerbate
dysfunction
production,
thereby
vicious
cycle.
While
mounting
evidence
implicates
etiology,
clinical
trials
therapies
have
not
produced
consistent
results.
this
review,
we
will
discuss
role
oxidative
AD,
innovative
strategies
evolved
based
on
better
complexity
mechanisms
dual
play
health
disease.
Acta Neuropathologica,
Journal Year:
2017,
Volume and Issue:
133(5), P. 665 - 704
Published: April 6, 2017
Tau
is
well
established
as
a
microtubule-associated
protein
in
neurons.
However,
under
pathological
conditions,
aberrant
assembly
of
tau
into
insoluble
aggregates
accompanied
by
synaptic
dysfunction
and
neural
cell
death
range
neurodegenerative
disorders,
collectively
referred
to
tauopathies.
Recent
advances
our
understanding
the
multiple
functions
different
locations
inside
outside
neurons
have
revealed
novel
insights
its
importance
diverse
molecular
pathways
including
signalling,
plasticity,
regulation
genomic
stability.
The
present
review
describes
physiological
pathophysiological
properties
how
these
relate
distribution
We
highlight
post-translational
modifications
tau,
which
are
pivotal
defining
modulating
localisation
roles
health
disease.
include
discussion
other
pathologically
relevant
changes
mutation
aggregation,
aspects
impinge
on
propensity
propagate,
potentially
drive
neuronal
loss,
diseased
brain.
Finally,
we
describe
cascade
events
that
may
be
driven
dysfunction,
impaired
axonal
transport,
alterations
synapse
mitochondrial
function,
activation
unfolded
response
defective
degradation.
It
important
fully
understand
attributed
since
this
will
provide
vital
information
involvement
development
pathogenesis
Such
knowledge
enable
determination
critical
should
targeted
potential
therapeutic
agents
developed
for
treatment
Chronic Stress,
Journal Year:
2017,
Volume and Issue:
1
Published: Feb. 1, 2017
The
brain
is
the
central
organ
of
stress
and
adaptation
to
because
it
perceives
determines
what
threatening,
as
well
behavioral
physiological
responses
stressor,
which
promote
("allostasis")
but
also
contribute
pathophysiology
("allostatic
load/overload")
when
overused
dysregulated.
adult
developing
possesses
a
remarkable
ability
show
structural
functional
plasticity
in
response
stressful
other
experiences,
including
neuronal
replacement,
dendritic
remodeling
synapse
turnover.
Stress
can
cause
an
imbalance
neural
circuitry
subserving
cognition,
decision
making,
anxiety
mood
that
increase
or
decrease
expression
those
behaviors
states.
This
imbalance,
turn,
affects
systemic
physiology
via
neuroendocrine,
autonomic,
immune
metabolic
mediators.
In
short
term,
these
changes
may
be
adaptive;
but,
if
threat
passes
state
persists
along
with
circuitry,
such
maladaptation
requires
intervention
combination
pharmacological
therapies.
There
are
important
sex
differences
how
responds
stressors.
Moreover,
adverse
early
life
experience,
interacting
alleles
certain
genes,
produces
lasting
effects
on
body
epigenetic
mechanisms.
While
prevention
key,
gives
hope
for
therapies
utilize
brain-body
interactions.
Policies
government
private
sector
health
"healthspan."
Human Molecular Genetics,
Journal Year:
2011,
Volume and Issue:
20(13), P. 2495 - 2509
Published: March 31, 2011
The
purpose
of
our
study
was
to
better
understand
the
relationship
between
mitochondrial
structural
proteins,
particularly
dynamin-related
protein
1
(Drp1)
and
amyloid
beta
(Aβ)
in
progression
Alzheimer's
disease
(AD).
Using
qRT-PCR
immunoblotting
analyses,
we
measured
mRNA
levels
genes
frontal
cortex
patients
with
early,
definite
severe
AD
control
subjects.
We
also
characterized
monomeric
oligomeric
forms
Aβ
these
patients.
immunoprecipitation/immunoblotting
analysis,
investigated
interaction
Drp1.
immunofluorescence
determined
localization
Drp1
intraneuronal
brains
primary
hippocampal
neurons
from
precursor
(AβPP)
transgenic
mice.
found
increased
expression
fission
Fis1
(fission
1)
decreased
fusion
Mfn1
(mitofusin
1),
Mfn2
2),
Opa1
(optic
atrophy
Tomm40.
matrix
gene
CypD
up-regulated
Results
analyses
suggest
that
abnormal
dynamics
increase
as
progresses.
Immunofluorescence
analysis
antibody
antibodies
6E10
A11
revealed
colocalization
Aβ.
interacts
monomers
oligomers
patients,
interactions
are
progression.
Primary
were
accumulated
had
lost
branches
degenerated,
indicating
may
cause
neuronal
degeneration.
These
findings
AD,
production
crucial
factors
fragmentation,
synaptic
damage.
Inhibiting,
be
a
therapeutic
strategy
reduce
damage
cognitive
decline
AD.
Proceedings of the National Academy of Sciences,
Journal Year:
2010,
Volume and Issue:
107(43), P. 18670 - 18675
Published: Oct. 11, 2010
Synaptic
dysfunction
and
the
loss
of
synapses
are
early
pathological
features
Alzheimer's
disease
(AD).
Synapses
sites
high
energy
demand
extensive
calcium
fluctuations;
accordingly,
synaptic
transmission
requires
levels
ATP
constant
fluctuation.
Thus,
mitochondria
vital
for
maintenance
function
through
normal
mitochondrial
metabolism,
distribution
trafficking,
modulation.
To
date,
there
has
been
no
analysis
alterations
in
associated
with
amyloid
pathology
an
β
(Aβ)-rich
milieu.
Here,
we
identified
differences
properties
vs.
nonsynaptic
populations
transgenic
mouse
brain,
which
overexpresses
human
mutant
form
precursor
protein
Aβ.
Compared
mitochondria,
showed
a
greater
degree
age-dependent
accumulation
Aβ
alterations.
The
pool
was
detected
at
age
as
young
4
mo,
well
before
onset
extracellular
accumulation.
Aβ-insulted
revealed
deficits
function,
shown
by
increased
permeability
transition,
decline
both
respiratory
activity
cytochrome
c
oxidase,
oxidative
stress.
Furthermore,
low
concentration
(200
nM)
significantly
interfered
trafficking
axons.
These
results
demonstrate
that
especially
Aβ-rich
more
susceptible
to
Aβ-induced
damage,
highlighting
central
importance
relevant
development
degeneration
AD.
Alzheimer s & Dementia,
Journal Year:
2018,
Volume and Issue:
14(9), P. 1171 - 1183
Published: June 12, 2018
Abstract
Introduction
Precision
medicine
methodologies
and
approaches
have
advanced
our
understanding
of
the
clinical
presentation,
development,
progression,
management
Alzheimer's
disease
(AD)
dementia.
However,
sex
gender
not
yet
been
adequately
integrated
into
many
these
approaches.
Methods
The
Society
for
Women's
Health
Research
Interdisciplinary
Network
on
AD,
comprised
an
expert
panel
scientists
clinicians,
reviewed
ongoing
published
research
related
to
differences
in
AD.
Results
current
review
is
a
result
this
Network's
efforts
aims
to:
(1)
highlight
state‐of‐the‐science
AD
field
differences;
(2)
address
knowledge
gaps
assessing
(3)
discuss
12
priority
areas
that
merit
further
research.
Discussion
exclusion
has
impeded
faster
advancement
detection,
treatment,
care
across
spectrum.
Greater
attention
will
improve
outcomes
both
sexes.
Human Molecular Genetics,
Journal Year:
2011,
Volume and Issue:
20(23), P. 4515 - 4529
Published: Aug. 25, 2011
Increasing
evidence
suggests
that
the
accumulation
of
amyloid
beta
(Aβ)
in
synapses
and
synaptic
mitochondria
causes
mitochondrial
failure
degeneration
Alzheimer's
disease
(AD).
The
purpose
this
study
was
to
better
understand
effects
Aβ
activity
alterations
neurons
from
a
mouse
model
AD.
Using
primary
well-characterized
precursor
protein
transgenic
(AβPP)
(Tg2576
line),
for
first
time,
we
studied
activity,
including
axonal
transport
mitochondria,
dynamics,
morphology
function.
Further,
also
nature
Aβ-induced
alterations,
cell
death
Tg2576
mice,
sought
determine
whether
mitochondria-targeted
antioxidant
SS31
could
mitigate
oligomeric
Aβ.
We
found
significantly
decreased
anterograde
movement,
increased
fission
fusion,
abnormal
proteins
defective
function
AβPP
mice
compared
with
wild-type
(WT)
neurons.
Transmission
electron
microscopy
revealed
large
number
small
structurally
damaged
broken
cristae
an
apoptotic
neuronal
relative
WT
Our
results
intraneuronal
Aβ,
leading
deficiencies,
ultimately
causing
neurodegeneration
cultures.
However,
restored
viability,
percentage
indicating
protects
toxicity.
Progress in Neurobiology,
Journal Year:
2013,
Volume and Issue:
108, P. 21 - 43
Published: July 11, 2013
Alzheimer's
disease
(AD)
is
an
age-related
devastating
neurodegenerative
disorder,
which
severely
impacts
on
the
global
economic
development
and
healthcare
system.
Though
AD
has
been
studied
for
more
than
100
years
since
1906,
exact
cause(s)
pathogenic
mechanism(s)
remain
to
be
clarified.
Also,
efficient
disease-modifying
treatment
ideal
diagnostic
method
are
unavailable.
Perturbed
cerebral
glucose
metabolism,
invariant
pathophysiological
feature
of
AD,
may
a
critical
contributor
pathogenesis
this
disease.
In
review,
we
firstly
discussed
features
metabolism
in
physiological
pathological
conditions.
Then,
further
reviewed
contribution
transportation
abnormality
intracellular
catabolism
dysfunction
pathophysiology,
proposed
hypothesis
that
multiple
cascades
induced
by
impaired
could
result
neuronal
degeneration
consequently
cognitive
deficits
patients.
Among
these
processes,
altered
functional
status
thiamine
brain
insulin
resistance
highly
emphasized
characterized
as
major
mechanisms.
Finally,
considering
fact
patients
exhibit
hypometabolism
possibly
due
impairments
signaling
also
discuss
some
potential
possibilities
uncover
biomarkers
from
abnormal
develop
drugs
targeting
at
repairing
impairment
correcting
abnormality.
We
conclude
plays
role
alterations
through
induction
factors
such
oxidative
stress,
mitochondrial
dysfunction,
so
forth.
To
clarify
causes,
pathogeneses
consequences
will
help
break
bottleneck
current
study
finding
biomarker
therapy.